CD96 Matched Antibody Pair (240) (APMAB-240LY)

Lee, P. S., Chau, B., Barman, I., Bee, C., Jashnani, A., Hogan, J. M., ... & Strop, P. (2021, January). Antibody blockade of CD96 by distinct molecular mechanisms. In Mabs (Vol. 13, No. 1, p. 1979800). Taylor & Francis.

Xie, C., Wang, Z., Li, Y., Wu, F., Xia, H., Lu, Y., ... & Kwok, K. W. (2021). Molecular characterization and expression of CD96 in Nile tilapia (Oreochromis niloticus) in response to different pathogens stimulus. Aquaculture Reports, 20, 100705.

Zhang, H., Liu, Q., Lei, Y., Zhou, J., Jiang, W., Cui, Y., ... & Ke, Z. (2021). Direct interaction between CD155 and CD96 promotes immunosuppression in lung adenocarcinoma. Cellular & molecular immunology, 18(6), 1575-1577.

Maas, R. J., Hoogstad-van Evert, J. S., Van der Meer, J. M., Mekers, V., Rezaeifard, S., Korman, A. J., ... & Dolstra, H. (2020). TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. Oncoimmunology, 9(1), 1843247.

Liu, F., Huang, J., He, F., Ma, X., Fan, F., Meng, M., ... & Zhang, L. (2020). CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma. Scientific reports, 10(1), 1-10.

Chiang, E. Y., de Almeida, P. E., de Almeida Nagata, D. E., Bowles, K. H., Du, X., Chitre, A. S., ... & Grogan, J. L. (2020). CD96 functions as a co‐stimulatory receptor to enhance CD8+ T cell activation and effector responses. European journal of immunology, 50(6), 891-902.

Sun, H., Huang, Q., Huang, M., Wen, H., Lin, R., Zheng, M., ... & Sun, C. (2019). Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology, 70(1), 168-183.

Deuss, F. A., Watson, G. M., Fu, Z., Rossjohn, J., & Berry, R. (2019). Structural basis for CD96 immune receptor recognition of nectin-like protein-5, CD155. Structure, 27(2), 219-228.

Georgiev, H., Ravens, I., Papadogianni, G., & Bernhardt, G. (2018). Coming of age: CD96 emerges as modulator of immune responses. Frontiers in immunology, 9, 1072.

Roman Aguilera, A., Lutzky, V. P., Mittal, D., Li, X. Y., Stannard, K., Takeda, K., ... & Smyth, M. J. (2018). CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. Oncoimmunology, 7(5), e1424677.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Rat Anti-CD96 Recombinant Antibody (AG49)

Rabbit Anti-CD96 Recombinant Antibody (CBXC-1661)

Rabbit Anti-CD96 Recombinant Antibody (CBR065G)

Human Anti-CD96 Recombinant Antibody (CBXC-1268)

Mouse Anti-CD96 Recombinant Antibody (CBFYC-1501)

Mouse Anti-CD96 Recombinant Antibody (CBYY-C0550)

Mouse Anti-CD96 Recombinant Antibody (CBYY-C1657)

Mouse Anti-CD96 Recombinant Antibody (3H8)

Rat Anti-CD96 Recombinant Antibody (3.3)

Rat Anti-CD96 Recombinant Antibody (6A6)

Isotype control